InvestmentJul 30, 2026, 06:12 AM
Braveheart Bio Announces IPO of 18.75M Shares at $15.00-$17.00
AI Summary
Braveheart Bio, Inc. announced its initial public offering of 18,750,000 shares of common stock, with an estimated price range of $15.00 to $17.00 per share. The company has applied to list its common stock on The Nasdaq Global Market under the symbol "BRVE". Underwriters have an option to purchase an additional 2,812,500 shares, and a cornerstone investor has expressed non-binding interest to purchase up to $75 million in shares. Proceeds will fund the advancement of BHB-1893's Phase 3 clinical trials for obstructive and non-obstructive hypertrophic cardiomyopathy, R&D personnel, and general corporate purposes.
Key Highlights
- Initial public offering of 18,750,000 common shares.
- Estimated IPO price range: $15.00 to $17.00 per share.
- Underwriters' option for 2,812,500 additional shares.
- Cornerstone investor interest for up to $75 million in shares.
- Expected net proceeds of approximately $274.5 million.
- Common stock to list on Nasdaq Global Market as "BRVE".
- LIONHEART-HCM (oHCM Phase 3) to start H2 2026.
- NOBLEHEART-HCM (nHCM Phase 3) to start H1 2027.
Price Impact